AAAAAA

   
Results: 1-8 |
Results: 8
A PHASE-I AND PHARMACOLOGICAL STUDY OF THE ORAL MATRIX METALLOPROTEINASE INHIBITOR, BAY 12-9566, IN COMBINATION WITH PACLITAXEL AND CARBOPLATIN
Authors: ECKHARDT SG RIZZO J BRITTEN C SIU L HUMPHREY R SMETZER L SORENSEN M SUNDARESAN P VONHOFF DD ROWINSKY EK
Citation: Sg. Eckhardt et al., A PHASE-I AND PHARMACOLOGICAL STUDY OF THE ORAL MATRIX METALLOPROTEINASE INHIBITOR, BAY 12-9566, IN COMBINATION WITH PACLITAXEL AND CARBOPLATIN, Annals of oncology, 9, 1998, pp. 614-614
A PHASE-I AND PHARMACOKINETIC (PK) STUDY OF DX-8951F, A NOVEL HEXACYCLIC CAMPTOTHECIN (CPT) ANALOG, ON A 30 MINUTE INFUSION DAILY FOR 5 DAYS EVERY 3 WEEK SCHEDULE
Authors: JOHNSON T GEYER C DEJAGER R ECKHARDT SG SMETZER L CLARK G COYLE J DRENGLER R VONHOFF D ROWINSKY E
Citation: T. Johnson et al., A PHASE-I AND PHARMACOKINETIC (PK) STUDY OF DX-8951F, A NOVEL HEXACYCLIC CAMPTOTHECIN (CPT) ANALOG, ON A 30 MINUTE INFUSION DAILY FOR 5 DAYS EVERY 3 WEEK SCHEDULE, Annals of oncology, 9, 1998, pp. 245-245
PROLONGED ADMINISTRATION OF BAY-12-9566, AN ORAL NONPEPTIDIC BIPHENYLMATRIX - A PHASE-I AND PHARMACOLOGICAL STUDY
Authors: ROWINSKY E HAMMOND L AYLESWORTH C HUMPHREY R SMETZER L SIU L WEISS G SMITH L THURMAN A RODRIGUEZ G SORENSEN M VONHOFF D ECKHARDT SG
Citation: E. Rowinsky et al., PROLONGED ADMINISTRATION OF BAY-12-9566, AN ORAL NONPEPTIDIC BIPHENYLMATRIX - A PHASE-I AND PHARMACOLOGICAL STUDY, Annals of oncology, 9, 1998, pp. 287-287
A PHASE-I AND PHARMACOKINETIC (PK) STUDY OF DOCETAXEL IN CANCER-PATIENTS WITH LIVER DYSFUNCTION DUE TO MALIGNANCIES
Authors: BAKER SD RAVDIN P AYLESWORTH C SMETZER L BRUNO R VERNILLET L PAZDUR R DOYLE G HAMMERSHAIMB L HOOKER E BURRIS HA ECKHARDT SG JOHNSON T KRAYNAK M HAMMOND L RODRIGUEZ G WEISS G ROWINSKY EK
Citation: Sd. Baker et al., A PHASE-I AND PHARMACOKINETIC (PK) STUDY OF DOCETAXEL IN CANCER-PATIENTS WITH LIVER DYSFUNCTION DUE TO MALIGNANCIES, Annals of oncology, 9, 1998, pp. 388-388
PHASE-I AND PHARMACOKINETIC (PK) STUDY OF THE DIARYLSULFONYLUREA LY295501 ADMINISTERED AS A SINGLE ORAL DOSE WEEKLY FOR 3 WEEKS EVERY 4 WEEKS
Authors: DIAB S BAKER SD HAMMOND L VILLALONA M ECKHARDT SG TINU C WEISS G KRAYNAK M AYLESWORTH C SMITH L RODRIGUEZ G DRENGLER R PATIL R SIU L ROTHENBERG M SMETZER L NYHART E STORNIOLO AM VONHOFF D ROWINSKY E
Citation: S. Diab et al., PHASE-I AND PHARMACOKINETIC (PK) STUDY OF THE DIARYLSULFONYLUREA LY295501 ADMINISTERED AS A SINGLE ORAL DOSE WEEKLY FOR 3 WEEKS EVERY 4 WEEKS, Annals of oncology, 9, 1998, pp. 440-440
PHASE-I CLINICAL AND PHARMACOLOGICAL STUDY OF ENILURACIL PLUS FLUOROURACIL IN PATIENTS WITH ADVANCED CANCER
Authors: SCHILSKY RL HOHNEKER J RATAIN MJ JANISCH L SMETZER L LUCAS VS KHOR SP DIASIO R VONHOFF DD BURRIS HA
Citation: Rl. Schilsky et al., PHASE-I CLINICAL AND PHARMACOLOGICAL STUDY OF ENILURACIL PLUS FLUOROURACIL IN PATIENTS WITH ADVANCED CANCER, Journal of clinical oncology, 16(4), 1998, pp. 1450-1457
A PHASE-I CLINICAL AND PHARMACOKINETIC STUDY OF THE ANGIOGENESIS INHIBITOR, TECOGALAN SODIUM
Authors: ECKHARDT SG BURRIS HA ECKARDT JR WEISS G RODRIGUEZ G ROTHENBERG M RINALDI D BARRINGTON R KUHN JG MASUO K SUDO K ATSUMI R OGUMA T HIGASHI L FIELDS S SMETZER L VONHOFF DD
Citation: Sg. Eckhardt et al., A PHASE-I CLINICAL AND PHARMACOKINETIC STUDY OF THE ANGIOGENESIS INHIBITOR, TECOGALAN SODIUM, Annals of oncology, 7(5), 1996, pp. 491-496
PHASE-II TRIAL OF DOCETAXEL IN PATIENTS WITH ADVANCED CUTANEOUS MALIGNANT-MELANOMA PREVIOUSLY UNTREATED WITH CHEMOTHERAPY
Authors: BEDIKIAN AY WEISS GR LEGHA SS BURRIS HA ECKARDT JR JENKINS J ETON O BUZAID AC SMETZER L VONHOFF DD BENJAMIN RS
Citation: Ay. Bedikian et al., PHASE-II TRIAL OF DOCETAXEL IN PATIENTS WITH ADVANCED CUTANEOUS MALIGNANT-MELANOMA PREVIOUSLY UNTREATED WITH CHEMOTHERAPY, Journal of clinical oncology, 13(12), 1995, pp. 2895-2899
Risultati: 1-8 |